• S&P 500: 1,342.64
  • Change: -0.69%
$6.49 -0.04 (-0.61%)
2/10/2012 4:00 PM

DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Current Price $6.49 Mkt Cap $359.31M
Open $6.44 P/E Ratio 3.20
Prev. Close $6.53 Div. (Yield) N/A (N/A)
Daily Range $6.35 - $6.50 Volume 393,850
52-Wk Range $4.20 - $10.19 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think DEPO will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

239 Outperform
16 Underperform
 

All-Star Players

56 Outperform
3 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top DEPO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

siri22 (< 20)
Submitted November 13, 2011

Hurt bt abt. But graise launch 150m in cash

Add Comment | Reply | Report this Post

zzlangerhans (99.27)
Submitted December 29, 2011

DepoMed's share price has recovered substantially from the lows of 4.3 seen after the failure of Breeze 3 in October. My question is, why? After the horrendous commercial performance of newly approved pain medications in the last few years, why would… More

Add Comment | Reply | Report this Post
DEPO VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about DEPO.

Recs

0
Member Avatar Coralreefer1 (32.90) Submitted: 1/24/2012 1:54:29 AM : Outperform Start Price: $6.24 DEPO Score: +1.28

Pharmaceuticals are on a roll lately

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar NuclearSteve (< 20) Submitted: 12/29/2011 12:49:57 PM : Outperform Start Price: $5.19 DEPO Score: +18.25

Article from Zacks Biotech Guy - Jason Napodano - trying a strategy where I set 10% stops on all these and let the winners run.

Report this Post Add Comment | Reply | Permalink

Recs

1
Member Avatar zzlangerhans (99.27) Submitted: 12/28/2011 7:10:08 PM : Underperform Start Price: $5.18 DEPO Score: -18.47

DepoMed's share price has recovered substantially from the lows of 4.3 seen after the failure of Breeze 3 in October. My question is, why? After the horrendous commercial performance of newly approved pain medications in the last few years, why would the share price rise going into the launch of Gralise? The only question is, in what month will disappointing revenue numbers first surface? Meanwhile, the company has yet to announce termination of development of Gabapentin GR for hot flashes. That negative catalyst should also surface in early 2012. DepoMed should be trading closer to the most recent cash position of 154M than the current cap of 284M.

Report this Post Add Comment | Reply | Permalink
View All 39 Pitches »

Leaderboard

Find the members with the highest scoring picks in DEPO.

Score Leader

zzlangerhans

zzlangerhans (99.27) Score: +282.72

The FDA approval curse claims yet another victim.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
Mattd46612 88.14 7/10/2007 Outperform NS $1.90 +241.58% -7.13% +248.71 2 Comments
learneda 82.47 7/19/2007 Outperform 1Y $2.30 +182.17% -8.87% +191.04 0 Comment
TheWINingest 72.18 7/12/2007 Outperform 5Y $2.39 +171.55% -7.18% +178.73 0 Comment
juanquita < 20 7/24/2007 Outperform NS $2.46 +163.82% -7.63% +171.45 0 Comment
certron 34.40 7/12/2007 Outperform 1Y $2.49 +160.71% -7.59% +168.30 0 Comment
rojostyle 98.16 5/18/2009 Outperform 3M $2.11 +207.58% +49.66% +157.92 0 Comment
RL542 81.68 4/30/2009 Outperform NS $2.08 +212.02% +55.16% +156.86 0 Comment
calekab 55.83 2/19/2010 Outperform 5Y $2.40 +170.42% +21.59% +148.82 0 Comment
yellowear1 20.75 2/18/2010 Outperform 5Y $2.41 +168.74% +21.13% +147.60 0 Comment
Devin65 < 20 2/24/2010 Outperform 5Y $2.43 +167.08% +21.99% +145.09 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackJMP 84.95 1/5/2012 Outperform NS $5.48 +18.43% +6.01% +12.42 0 Comment
TrackAurigaUSA < 20 9/30/2011 Outperform NS $5.48 +18.43% +17.40% +1.03 0 Comment
TrackJGreenblatt 85.34 8/15/2011 Outperform 5Y $5.21 +24.57% +12.43% +12.14 1 Comment
TrackCarisandCo 88.70 10/21/2009 Outperform NS $3.47 +87.03% +23.22% +63.81 0 Comment
trackmerriman 70.89 10/5/2009 Outperform NS $5.85 -56.05% +7.29% -63.34 2/18/2010 @ $2.57 0 Comment
TrackZacks 71.09 6/25/2009 Outperform 3M $2.82 -2.49% +15.58% -18.07 7/8/2010 @ $2.75 1 Comment
TrackJGreenblatt 85.34 8/18/2008 Outperform 1Y $4.22 -17.06% -24.61% +7.55 8/17/2009 @ $3.50 2 Comments
TrackRothCapital < 20 6/20/2008 Outperform NS $3.40 +141.76% +1.83% +139.94 5/3/2011 @ $8.22 0 Comment
TrackTWeisel 91.97 3/15/2007 Outperform NS $3.24 +100.31% +2.62% +97.69 0 Comment
TrackMatrix 92.79 8/28/2006 Underperform NS $4.26 +52.35% +10.48% -41.87 0 Comment

Featured Broker Partners